Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Zhuhai Beihai Biotech Co., Ltd
- Target Recruit Count
- 48
- Registration Number
- NCT06732531
An Relative Bioavailability Study of BH006 for Injection in Healthy Subjects
Early Phase 1
Not yet recruiting
- Conditions
- Bioavailability
- Interventions
- Drug: BH006 for injection
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Zhuhai Beihai Biotech Co., Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT06427681
A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Zhuhai Beihai Biotech Co., Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT06232863
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
🇨🇳The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
Phase I Clinical Trial of BH002 in Patients With Advanced Solid Tumors
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Zhuhai Beihai Biotech Co., Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT06231277
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Bioequivalence Study of Docetaxel Injection in Patients With Solid Tumours
Phase 3
Completed
- Conditions
- DocetaxelSolid TumoursBioequivalence
- Interventions
- Drug: BH009 (Docetaxel injection)
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Zhuhai Beihai Biotech Co., Ltd
- Target Recruit Count
- 46
- Registration Number
- NCT04889599
- Locations
- 🇮🇳
HCG City Cancer center, Andra, India
🇮🇳Nirmal Hospital Pvt. Ltd, Gujrat, India
🇮🇳HCG Manavata Cancer Centre, Mahara, India